{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:21:33Z","timestamp":1791411693305,"version":"4.3.3"},"reference-count":60,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eisai Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2025.2600875","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:01:47Z","timestamp":1769616107000},"page":"250-262","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer\u2019s disease: a modelling study"],"prefix":"10.1080","volume":"29","author":[{"given":"Oliver","family":"Burn","sequence":"first","affiliation":[{"name":"Source Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Molloy","sequence":"additional","affiliation":[{"name":"Source Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kanekiyo","sequence":"additional","affiliation":[{"name":"Eisai Inc","place":["Nutley, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd","place":["Hatfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rothwell","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd","place":["Hatfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Janice","family":"Pan","sequence":"additional","affiliation":[{"name":"Eisai Inc","place":["Nutley, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Trueman","sequence":"additional","affiliation":[{"name":"Source Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Scottish Brain Sciences","place":["Edinburgh, UK"]},{"name":"Department of Medicine, University of St Andrews","place":["St Andrews, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.10.009"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn2001238"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002242"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100472"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-01629-1"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610215000757"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2014-1642"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213954"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140741"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030952"},{"key":"e_1_3_5_13_1","unstructured":"U.S. Food and Drug Administration. FDA News Release: FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. ; 2023."},{"key":"e_1_3_5_14_1","unstructured":"Lecanemab licensed for adult patients in the early stages of Alzheimer\u2019s disease. 2024. https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease"},{"key":"e_1_3_5_15_1","unstructured":"European Medicines Agency. Leqembi\u00ae (lecanemab) is the first medicine that slows progression of early Alzheimer\u2019s disease to be authorized in the European Union. https:\/\/wwweisaicom\/news\/2025\/news202532html. ; 2025."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00373-5"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00473-w"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00460-1"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.9.1078"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00492-7"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.334"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.6.1138"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000201851.52707.c9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S22265"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011310020011"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-191055"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-012-0010-7"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.8.1091"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.11.002"},{"key":"e_1_3_5_31_1","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease; 2018."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.05.004"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12811"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00272-1"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7448"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.10.003"},{"key":"e_1_3_5_37_1","unstructured":"Bloudek L et al. Abstract 1958. Comparison of contemporary clinical dementia rating scale-sum of boxes (CDR-SB) disease progression models in Alzheimer\u2019s Disease. Alzheimer\u2019s & Parkinson\u2019s Diseases Conference. 2025"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-101758"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720512803569046"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.01.011"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205015666180119092427"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210305"},{"key":"e_1_3_5_43_1","unstructured":"Institute for Clinical and Economic Review (ICER). Aducanumab for Alzheimer\u2019s Disease: effectiveness and Value. Final Evidence Report and Meeting Summary [Internet]. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_ALZ_Final_Report_080521-1.pdf"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013591"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03353-w"},{"key":"e_1_3_5_46_1","unstructured":"Eisai. Lecanemab Summary of Product characteristics (SPC). 2024. https:\/\/www.medicines.org.uk\/emc\/product\/15908\/smpc"},{"key":"e_1_3_5_47_1","first-page":"511","article-title":"New International Pharmaco-Economic Collaboration on Alzheimer\u2019s Disease (IPECAD) open-source model framework for the health technology assessment of Early Alzheimer\u2019s disease treatment: development and use cases","author":"Handels R","year":"2024","unstructured":"Handels R, Herring WL, Grimm S, et al. New International Pharmaco-Economic Collaboration on Alzheimer\u2019s Disease (IPECAD) open-source model framework for the health technology assessment of Early Alzheimer\u2019s disease treatment: development and use cases. Value in Health. 2024;28(4):511\u2013518.","journal-title":"Value in Health"},{"key":"e_1_3_5_48_1","unstructured":"Anderson RKM Wittenberg R Handels R et al. Economic modelling of disease-modifying therapies in Alzheimer\u2019s disease. London School of Economics and Political Science London UK; 2018."},{"key":"e_1_3_5_49_1","unstructured":"Bodnar SRJTWYCLBC. Comparison OF CLINICAL DEMENTIA RATING SCALE-SUM of boxes (CDR-SB) disease progression models in Alzheimer\u2019s disease. Poster presented at the Alzheimer\u2019s & Parkinson\u2019s Diseases Conference 2025 Annual Meeting; April 1-5; 2025."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00649-y"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-02720-y"},{"key":"e_1_3_5_52_1","unstructured":"EMA. Leqembi (lecanemab)EPAR. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345777"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14134"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz70861_108905"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01413-y"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8932"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdata.2020.00024"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73911-6"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S62323"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12974"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2600875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:01:49Z","timestamp":1769616109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2600875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2600875"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2600875","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}